Global Snake Antivenom Market Size study & Forecast, by Type ( Polyvalent Heterologous, Monovalent Heterologous) by Application ( Hospitals, Clinics), and Regional Analysis, 2022-2029

Global Snake Antivenom Market Size study & Forecast, by Type ( Polyvalent Heterologous, Monovalent Heterologous) by Application ( Hospitals, Clinics), and Regional Analysis, 2022-2029

Global Snake Antivenom Market is valued at approximately USD 294.8 million in 2021 and is anticipated to grow with a healthy growth rate of more than 7.7% over the forecast period 2022-2029. Antivenoms work by boosting the immunological response that occurs in humans after being bitten by a snake. They are made by injecting snake venom into donor animals like sheep or horses. Strong immune systems and the generation of robust antibodies that can attach to snake venom components in these animals enable their own natural defenses to eliminate these toxins.. The Snake Antivenom market is expanding because of factors such as the rising incidence of snakebites and rising government initiatives to raise awareness.

In tropical and subtropical areas, snakebites are the health issue that receives the least attention. The World Health Organization (WHO) estimates that 2.7 million cases of snake envenoming are recorded annually on a global scale. Venomous bites are thought to be the cause of 81,000 to 138,000 fatalities annually. The geographic distribution of these interactions varies greatly. In Asia alone, there are almost 1.7 million snakebite incidents reported per year. Each year, a significant number of snakebites occur in nations in Africa and Latin America as well. One of the main causes of the worldwide increase in snake envenoming incidents is the need for novel products, driving market growth. Additionally, the only medication that may effectively undo the symptoms of snake envenoming is antivenom. Snake's antivenom is a component of basic medical care and is included among the ""Essential Medicines"" by the WHO. Furthermore, several government and non-government organizations started a number of projects and initiatives to spread the word about snakebite treatment in an effort to lower the fatality rate from snakebites. In order to reduce the number of disabilities and fatalities by snakebites by the year 2030, the WHO launched a strategy for preventing and controlling snakebite envenoming in May 2019. These initiatives have aided these organizations in increasing accessibility and raising awareness in low- and middle-income nations. However, the Lack of adequate price regulation and reimbursement policy stifles market growth throughout the forecast period of 2022-2029.

The key regions considered for the Global Snake Antivenom Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America dominated the market in terms of revenue, owing to the presence of key players, and research initiatives by government authorities. Whereas Asia Pacific is expected to grow with the highest CAGR during the forecast period, owing to factors such as increasing snake envenoming’s, an increase in the number of collaborations for research and development, geographic expansion of key players, and active participation of government and nonprofit organizations in the market space.

Major market player included in this report are:
MicroPharm Ltd
BTG International Inc.
VINS Bioproducts Limited
Pfizer Inc.
SEQIRUS (CSL Limited)
Inosan Biopharma
South Africa Vaccine Producers
Rare Disease Therapeutics, Inc.
Incepta Vaccine Ltd.
Bioclon Institute

Recent Developments in the Market:
In January 2019, BTG International Inc. collaborated with OMNY to increase the usability of its snake antivenom CroFab through distributed ledger technology.
In November 2020, CSL Sequris (a CSL Limited subsidiary) financed over USD 601.5 million in building a manufacturing facility in the Southern Hemisphere to produce Australian antivenoms, as well as the Q-fever vaccine and pandemic flu vaccine.

Global Snake Antivenom Market Report Scope:

Historical Data 2019-2020-2021
Base Year for Estimation 2021
Forecast period 2022-2029
Report Coverage Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered Type, Application, Region
Regional Scope North America; Europe; Asia Pacific; Latin America; Rest of the World
Customization Scope Free report customization (equivalent up to 8 analyst’s working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and Type offerings of key players.

The detailed segments and sub-segment of the market are explained below:

By Type:
Polyvalent Heterologous
Monovalent Heterologous

By Type:
Hospitals
Clinics

By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
RoLA
Rest of the World

Companies Mentioned

MicroPharm Ltd
BTG International Inc.
VINS Bioproducts Limited
Pfizer Inc.
SEQIRUS (CSL Limited)
Inosan Biopharma
South Africa Vaccine Producers
Rare Disease Therapeutics, Inc.
Incepta Vaccine Ltd.
Bioclon Institute

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.